1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Spago Nanomedical AB

Spago Nanomedical AB

SSTO:SPAGO
0.10
SEK
0.00
(0.00%)
93.01MMarket Cap
Nov 05Next Earn
Spago Nanomedical AB
STO:SPAGO
(Nasdaq Stockholm)

Recent

price

0.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
2.82
0.23
0.04
0.01
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
- -
- -
Revenue per Share
-2.06
-4.88
-0.86
-0.87
-0.69
-0.58
-0.63
-0.45
-0.67
-0.46
-0.67
-0.41
-0.3
-0.11
-0.07
- -
Basic EPS, GAAP
-22.57
-8.76
-2.39
-2
-1.25
-1.42
-1.72
-1.6
-1.3
-0.62
-0.69
-0.44
-0.33
-0.12
-0.08
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.05
6.73
5.9
5.22
5.01
4.87
4.74
4.61
4.13
3.35
2.99
1.46
0.15
0.07
0.05
0.04
Book Value per Share
-1.59
1.88
-2.4
-0.7
1.04
0.67
1.24
0.54
0.34
0.58
0.79
0.43
0.15
0.07
0.05
0.04
Tangible Book Value per Share
- -
1
6
7
10
13
15
25
30
41
58
95
139
296
376
568
Basic Weighted Avg Shares
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
2
- -
- -
Sales/Revenue/Turnover
-73.9
-1,605.41
-2,209.21
-10,874.07
- -
-12,584.48
-18,993.62
- -
-66,956.67
-5,541.81
-5,919.24
-3,708.25
-3,533.25
-1,746.73
-6,059.27
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-5
-5
-6
-7
-8
-9
-11
-20
-19
-39
-39
-42
-33
-27
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-72.88
-2,078.83
-2,286.84
-11,353.7
- -
-13,000
-20,121.28
- -
-67,370
-5,534.5
-5,919.85
-3,718.88
-3,509.81
-1,701.15
-6,076.43
- -
Profit Margin (%)
- -
17
6
13
19
15
27
13
11
27
48
56
40
33
31
32
Working Capital
- -
- -
16
15
6
6
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
13
42
40
56
65
72
108
122
138
160
185
197
41
33
31
32
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-16.75
-13.15
-13.68
-11.57
-10.99
-10.53
-9.65
-15.56
-12.73
-22.68
-20.52
-35.41
-87.21
-83.01
- -
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
663
663
798
Market Capitalization
77
70
93

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
36
30
37
Cash, Cash Equivalents & STI
30
26
33
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
5
5
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.83%
-16.73%
-7.49%
Free Cash Flow
13.61%
6.21%
-18.26%
Net Income, GAAP
20.22%
14.63%
-18.32%
Sales/Revenue/Turnover
- -
29.71%
-77.13%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
1
2
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.02
-0.02
-0.11
2025
-0.02
-0.02
- -
-0.01
-0.07
2026
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Spago Nanomedical AB (publ) Spago Nanomedical AB (publ) (SPAGO.ST) is a Sweden-based clinical-stage nanomedicine company focused on developing nanoparticle-based products for improved imaging diagnostics and treatment of cancer and other severe diseases; its operations leverage a proprietary patented platform of polymeric materials that enable physiological tumor accumulation for enhanced precision in diagnostics and therapeutics. Founded in 1999 and headquartered in Lund, Sweden, the company advances two core pipeline projects: SpagoPix (SN132D/peglfosimer manganese), a gadolinium-free MRI contrast agent in phase II for breast, liver, and pancreas cancers that selectively accumulates in tumor tissue to reduce false positives and improve scan accuracy; and Tumorad (SN201/177Lu-SN201), a preclinical-to-phase I/IIa radiopharmaceutical therapy using radioactive isotopes in functional nanoparticles for targeted radiation of solid, aggressive, and metastatic tumors while minimizing off-target effects. SpagoPix has demonstrated good contrast enhancement and safety in initial clinical data from the phase I SPAGOPIX-01 study, with results published in Investigative Radiology, while Tumorad has shown promising preclinical tumor accumulation, delayed growth, and favorable early imaging in the ongoing Tumorad-01 phase I/IIa dose-escalation study across multiple tumor types at sites in Australia. Recent developments include an oversubscribed rights issue in November 2025 raising approximately SEK 25 million to fund Tumorad advancement, progression to higher doses in Tumorad-01 following positive data monitoring committee review in March 2025, publication of SpagoPix clinical data to support partnering discussions, a proposed board refresh with oncology experts Alan Raffensperger as chairman and Mikael von Euler as member, and the release of the 2024 annual report highlighting accelerated Tumorad focus; formerly known as Spago Imaging publ AB, the company lists on Nasdaq First North Growth Market in Stockholm and employs about nine staff with global partnering ambitions in high-need oncology markets.